Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016

Description: Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016

Summary

'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016', provides an overview of the Neuromyelitis Optica (Devic's Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)
- The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuromyelitis Optica (Devic's Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Neuromyelitis Optica (Devic's Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Neuromyelitis Optica (Devic's Syndrome) Overview
Therapeutics Development
Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview
Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies
Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes
Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Alexion Pharmaceuticals Inc
Biogen Inc
Bionure Farma, S.L.
Chugai Pharmaceutical Co., Ltd.
Clene Nanomedicine, Inc.
HanAll Biopharma Co., Ltd.
Karus Therapeutics Limited
LFB S.A.
Marathon Pharmaceuticals, LLC
MedImmune, LLC
Opexa Therapeutics, Inc.
Shire Plc
Takeda Pharmaceutical Company Limited
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANV-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNMAU-8 - Drug Profile
OPX-212 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

rituximab - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

SA-237 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Small Molecule for Neuromyelitis Optica - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

ublituximab - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects

Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones

Featured News & Press Releases


Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)

Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol

May 08, 2015: Initiation Of Phase I Clinical Program

Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting

Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned

Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica

Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program

Aug 27, 2014: Clene Files Investigational New Drug Application With FDA

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis

Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA

Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles

Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion

Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2016

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma, S.L., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Clene Nanomedicine, Inc., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB S.A., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2016

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2016
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3927203/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016
Web Address: http://www.researchandmarkets.com/reports/3927203/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Single User</th>
<th>Enterprisewide</th>
<th>Site License</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2000</td>
<td>USD 6000</td>
<td>USD 4000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World